Fachrepositorium Lebenswissenschaften

8 Treffer

Suche

Publisso-Menue

Serum zinc as a biomarker to predict the efficacy of immune checkpoint inhibitors in cancers

2025 . Wang, Jingliang | Wang, Weihao | Liu, Bin | Zhao, Rui | Zhao, Jing | Jiang, Fengxian | Xu, Wei | Zhang, Zhizhao | Ran, Pancen | Shu, Yang | Wang, Yahui | Pan, Liying | Liu, Lei | Luan, Fang | Fu, Guobin

In silico identification of promising PD-L1 inhibitors from selected indian medicinal plants for treatment of triple negative breast cancer

2025 . Ahmed, Sk. Faisal | Hossain, Md. Shohel | Mondal, Amalesh | Shahariar , Musab | Shahariar, Musab | Sumya, Shormila Akter | Rizu, Nahid Sultan | Barsha, Lamia Hasan Joarder

The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis

2025 . Guo, Qian | Dong, Dong | Dang, Zihan | Huang, Shuman | Qiao, Xinjie | Zhang, Baiquan | zhao, yulin

Contrast-enhanced ultrasound with VEGFR2-targeted microbubbles for monitoring combined anti-PD-L1/anti-CTLA-4 immunotherapy effects in a murine melanoma model with immunohistochemical validation

2025 . , Felix | Antons, Melissa J. | Blume, Larissa V. | Hirner-Eppeneder, Heidrun | Kloiber-Langhorst, Sandra | Cimic, Amra | Stueckl, Jennifer | Tardy, Isabelle | Burkard, Tanja | Ricke, Jens | Kunz, Wolfgang G. | Clevert, Dirk-Andre | Heimer, Maurice M. | Cyran, Clemens C.

Hepatitis B virus X protein (HBx)-mediated immune modulation and prognostic model development in hepatocellular carcinoma

2025 . Zhong, Jianhua | Li, Yuetong | Liu, Yang | Qiao, Jie | Wu, Yiling | Kong, Xinyi | Qi, Miao | Lin, Yiqi | Yao, Yaqi | Jin, Ying | Bi, Changlong | Zhai, Aixia

Contemporaneous symptom networks for multidimensional symptom experience in lung cancer survivors of immunotherapy: A network analysis

2025 . Gao, Hang | Wen, Xiaoxue | Sun, Xiaoli | Liu, Yuwei | Hou, Jianwen | Zheng, Danwen | Chen, Hejia | Ma, Lingfang | Zhou, Yufang | Yu , Xinyan

Expression of plant-produced anti-PD-L1 antibody with anoikis sensitizing activity in human lung cancer cells via., suppression on epithelial-mesenchymal transition

2022 . Phetphoung, Thareeya | Malla, Ashwini | Rattanapisit, Kaewta | Pisuttinusart, Nuttapat | Damrongyot, Naruechai | Joyjamras, Keerati | Chanvorachote, Pithi | Phakham, Tanapati | Wongtangprasert, Tossapon | Strasser, Richard | Chaotham, Chatchai | Phoolcharoen, Waranyoo

ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models